Hong Kong Stock Movers: mRNA Concept Stocks Lead Gains, CanSinoBIO (06185) Surges Over 17% as Moderna's mRNA Neoantigen Therapy Set to Debut at ESMO Congress

Stock News09-30 10:02

mRNA concept stocks are leading the gains, with CanSinoBIO (06185) rising 16.78% to HK$36.32 as of press time.

Everest Medicines (01952) is up 4.29% at HK$29.18, 3D Medicines (01244) has gained 1.94% to HK$2.89, and Metis TechBio-P (07666) is trading 1.44% higher at HK$16.22.

On the news front, on September 21, Moderna announced that three research abstracts for its individualized mRNA neoantigen therapy co-developed with Merck have been accepted and will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in October.

According to Huaxin Securities, cancer vaccines represent a major breakthrough direction for mRNA technology in the future. Infectious disease vaccines are constrained by epidemic prevention and control, while the oncology field has substantial unmet demand, with the global cancer patient population continuing to grow. mRNA cancer vaccines are the core pathway for the market value of mRNA technology to leap forward.

Notably, on August 25, CanSinoBIO signed a "Strategic Cooperation Framework Agreement for the Co-Development of mRNA Personalized Therapeutic Tumor Vaccines" with Dpu Biotech.

Previously in the mRNA field, CanSinoBIO had already laid out mRNA vaccine research and development for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer. Everest Medicines plans to launch an IIT Ib study of its mRNA vaccine EVM16 in the fourth quarter of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154987922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154987922","market":"fut","top_or_hot":-1,"title":"Hong Kong Stock Movers: mRNA Concept Stocks Lead Gains, CanSinoBIO (06185) Surges Over 17% as Moderna's mRNA Neoantigen Therapy Set to Debut at ESMO Congress","media":"Stock News","content":"<p>mRNA concept stocks are leading the gains, with <b>CanSinoBIO</b> (<b>06185</b>) rising 16.78% to HK$36.32 as of press time.<br><br><b>Everest Medicines</b> (<b>01952</b>) is up 4.29% at HK$29.18, <b>3D Medicines</b> (<b>01244</b>) has gained 1.94% to HK$2.89, and <b>Metis TechBio-P</b> (<b>07666</b>) is trading 1.44% higher at HK$16.22.<br><br>On the news front, on September 21, Moderna announced that three research abstracts for its individualized mRNA neoantigen therapy co-developed with Merck have been accepted and will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in October.<br><br>According to Huaxin Securities, cancer vaccines represent a major breakthrough direction for mRNA technology in the future. Infectious disease vaccines are constrained by epidemic prevention and control, while the oncology field has substantial unmet demand, with the global cancer patient population continuing to grow. mRNA cancer vaccines are the core pathway for the market value of mRNA technology to leap forward.<br><br>Notably, on August 25, <b>CanSinoBIO</b> signed a \"Strategic Cooperation Framework Agreement for the Co-Development of mRNA Personalized Therapeutic Tumor Vaccines\" with Dpu Biotech.<br><br>Previously in the mRNA field, <b>CanSinoBIO</b> had already laid out mRNA vaccine research and development for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer. <b>Everest Medicines</b> plans to launch an IIT Ib study of its mRNA vaccine EVM16 in the fourth quarter of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movers: mRNA Concept Stocks Lead Gains, CanSinoBIO (06185) Surges Over 17% as Moderna's mRNA Neoantigen Therapy Set to Debut at ESMO Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movers: mRNA Concept Stocks Lead Gains, CanSinoBIO (06185) Surges Over 17% as Moderna's mRNA Neoantigen Therapy Set to Debut at ESMO Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-30 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>mRNA concept stocks are leading the gains, with <b>CanSinoBIO</b> (<b>06185</b>) rising 16.78% to HK$36.32 as of press time.<br><br><b>Everest Medicines</b> (<b>01952</b>) is up 4.29% at HK$29.18, <b>3D Medicines</b> (<b>01244</b>) has gained 1.94% to HK$2.89, and <b>Metis TechBio-P</b> (<b>07666</b>) is trading 1.44% higher at HK$16.22.<br><br>On the news front, on September 21, Moderna announced that three research abstracts for its individualized mRNA neoantigen therapy co-developed with Merck have been accepted and will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in October.<br><br>According to Huaxin Securities, cancer vaccines represent a major breakthrough direction for mRNA technology in the future. Infectious disease vaccines are constrained by epidemic prevention and control, while the oncology field has substantial unmet demand, with the global cancer patient population continuing to grow. mRNA cancer vaccines are the core pathway for the market value of mRNA technology to leap forward.<br><br>Notably, on August 25, <b>CanSinoBIO</b> signed a \"Strategic Cooperation Framework Agreement for the Co-Development of mRNA Personalized Therapeutic Tumor Vaccines\" with Dpu Biotech.<br><br>Previously in the mRNA field, <b>CanSinoBIO</b> had already laid out mRNA vaccine research and development for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer. <b>Everest Medicines</b> plans to launch an IIT Ib study of its mRNA vaccine EVM16 in the fourth quarter of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07666","symbol_name":"剂泰科技-P","start_time":0,"source_url":"","article_id":"1154987922","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154987922","pubTimestamp":1790733739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"mRNA concept stocks are leading the gains, with CanSinoBIO (06185) rising 16.78% to HK$36.32 as of press time.Everest Medicines (01952) is up 4.29% at HK$29.18, 3D Medicines (01244) has gained 1.94%...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07666":"剂泰科技-P","BK1161":"生物科技","KCAI":"KraneShares China Alpha Index ETF","01952":"云顶新耀","BK1574":"生物医药B类股","06185":"康希诺生物","BK4588":"碎股","BK1515":"抗疫概念","01244":"思路迪医药股份","BK4585":"ETF&股票定投概念","BK1583":"高瓴概念","VXUS":"国际股票ETF-Vanguard","BK1191":"制药"},"translate_title":"港股走势：mRNA概念股领涨，康希诺生物（06185）飙升逾17%，Moderna的mRNA新抗原疗法将在ESMO大会上首次亮相","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"07666":1,"KCAI":1,"01244":1,"01952":1,"06185":1},"content_text":"mRNA concept stocks are leading the gains, with CanSinoBIO (06185) rising 16.78% to HK$36.32 as of press time.Everest Medicines (01952) is up 4.29% at HK$29.18, 3D Medicines (01244) has gained 1.94% to HK$2.89, and Metis TechBio-P (07666) is trading 1.44% higher at HK$16.22.On the news front, on September 21, Moderna announced that three research abstracts for its individualized mRNA neoantigen therapy co-developed with Merck have been accepted and will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in October.According to Huaxin Securities, cancer vaccines represent a major breakthrough direction for mRNA technology in the future. Infectious disease vaccines are constrained by epidemic prevention and control, while the oncology field has substantial unmet demand, with the global cancer patient population continuing to grow. mRNA cancer vaccines are the core pathway for the market value of mRNA technology to leap forward.Notably, on August 25, CanSinoBIO signed a \"Strategic Cooperation Framework Agreement for the Co-Development of mRNA Personalized Therapeutic Tumor Vaccines\" with Dpu Biotech.Previously in the mRNA field, CanSinoBIO had already laid out mRNA vaccine research and development for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer. Everest Medicines plans to launch an IIT Ib study of its mRNA vaccine EVM16 in the fourth quarter of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154987922","isCrawlerRequest":true}